The half-life (t1/2) determined by fitting the decay data with the Hill model shows a 30–200-fold extended half-life and distinctly different protection profiles of tau purified from AD brains with different CSA profiles (S1 Fig). The gene discussed is MAPT; the disease is Alzheimer disease.